- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00401193
Efficacy and Safety of XP12B in Women With Menorrhagia
April 23, 2015 updated by: Ferring Pharmaceuticals
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia
The purpose of this study is to determine whether XP12B is effective and safe in the treatment of women with heavy menstrual bleeding associated with menorrhagia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
304
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Investigative Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85015
- Investigative Site
-
Tucson, Arizona, United States, 85712
- Investigative Site
-
Tucson, Arizona, United States, 85710
- Investigative Site
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Investigative Site
-
Searcy, Arkansas, United States, 72143
- Investigative Site
-
-
California
-
Los Alamitos, California, United States, 90720
- Investigative Site
-
Los Angeles, California, United States, 90027
- Investigative Site
-
San Diego, California, United States, 92108
- Investigative Site
-
-
Colorado
-
Denver, Colorado, United States, 80202
- Investigative Site
-
-
Connecticut
-
Groton, Connecticut, United States, 06340
- Investigative Site
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Investigative Site
-
Jacksonville, Florida, United States, 32216
- Investigative Site
-
Lighthouse Point, Florida, United States, 33064
- Investigative Site
-
Miami, Florida, United States, 33186
- Investigative Site
-
Miami Beach, Florida, United States, 33141
- Investigative Site
-
New Port Richey, Florida, United States, 34652
- Investigative Site
-
Sarasota, Florida, United States, 34233
- Investigative Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30328
- Investigative Site
-
Decatur, Georgia, United States, 30033
- Investigative Site
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Investigative Site
-
Idaho Falls, Idaho, United States, 83404
- Investigative Site
-
-
Indiana
-
Bloomington, Indiana, United States, 47403
- Investigative Site
-
-
Kansas
-
Newton, Kansas, United States, 67114
- Investigative Site
-
Overland Park, Kansas, United States, 66215
- Investigative Site
-
-
Louisiana
-
Marrero, Louisiana, United States, 70072
- Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21230
- Investigative Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Investigative Site
-
Bingham Farms, Michigan, United States, 48025
- Investigative Site
-
Grand Rapids, Michigan, United States, 49506
- Investigative Site
-
Paw Paw, Michigan, United States, 49079
- Investigative Site
-
St. Clair Shores, Michigan, United States, 48081
- Investigative Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- Investigative Site
-
-
Montana
-
Missoula, Montana, United States, 59808
- Investigative Site
-
-
Nebraska
-
McCook, Nebraska, United States, 69001
- Investigative Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
- Investigative Site
-
-
New Jersey
-
Lawrenceville, New Jersey, United States, 08648
- Investigative Site
-
Moorestown, New Jersey, United States, 08057
- Investigative Site
-
New Brunswick, New Jersey, United States, 08903
- Investigative Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87131
- Investigative Site
-
-
New York
-
New York, New York, United States, 10017
- Investigative Site
-
Rochester, New York, United States, 14621
- Investigative Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27713
- Investigative Site
-
Raleigh, North Carolina, United States, 27607
- Investigative Site
-
Winston-Salem, North Carolina, United States, 27103
- Investigative Site
-
-
North Dakota
-
Bismarck, North Dakota, United States, 58501
- Investigative Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Investigative Site
-
Cleveland, Ohio, United States, 44121
- Investigative Site
-
Gallipolis, Ohio, United States, 45631
- Investigative Site
-
Zanesville, Ohio, United States, 43701
- Investigative Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Investigative Site
-
Oklahoma City, Oklahoma, United States, 73104
- Investigative Site
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Investigative Site
-
Portland, Oregon, United States, 97205
- Investigative Site
-
-
Pennsylvania
-
Levittown, Pennsylvania, United States, 19056
- Investigative Site
-
Philadelphia, Pennsylvania, United States, 19104
- Investigative Site
-
Philadelphia, Pennsylvania, United States, 19114
- Investigative Site
-
Phoenixville, Pennsylvania, United States, 19460
- Investigative Site
-
Strafford, Pennsylvania, United States, 19087
- Investigative Site
-
Wexford, Pennsylvania, United States, 15090
- Investigative Site
-
Wynnewood, Pennsylvania, United States, 19096
- Investigative Site
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Investigative Site
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57104
- Investigative Site
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Investigative Site
-
Clarksville, Tennessee, United States, 37043
- Investigative Site
-
Nashville, Tennessee, United States, 37203
- Investigative Site
-
-
Texas
-
Austin, Texas, United States, 78737
- Investigative Site
-
Bryan, Texas, United States, 77802
- Investigative Site
-
Fort Worth, Texas, United States, 76132
- Investigative Site
-
Houston, Texas, United States, 77030
- Investigative Site
-
Plano, Texas, United States, 75093
- Investigative Site
-
Temple, Texas, United States, 46502
- Investigative Site
-
Waco, Texas, United States, 76712
- Investigative Site
-
Webster, Texas, United States, 77598
- Investigative Site
-
Woodlands, Texas, United States, 77380
- Investigative Site
-
-
Utah
-
Pleasant Grove, Utah, United States, 84062
- Investigative Site
-
Salt Lake City, Utah, United States, 84124
- Investigative Site
-
West Jordan, Utah, United States, 84088
- Investigative Site
-
West Valley City, Utah, United States, 84120
- Investigative Site
-
-
Vermont
-
Burlington, Vermont, United States, 05401
- Investigative Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Investigative Site
-
Richmond, Virginia, United States, 23225
- Investigative Site
-
-
Washington
-
Renton, Washington, United States, 98055
- Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 49 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Women with menorrhagia
- 18-49 years of age
- Regularly occurring menstrual periods
Exclusion Criteria:
- History or presence of clinically significant disease or abnormalities that may confound the study
- History of bilateral oophorectomy or hysterectomy
- Hormone therapy for birth control
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
3900 mg/Day
Other Names:
1950 mg/Day
Other Names:
|
Experimental: 2
|
3900 mg/Day
Other Names:
1950 mg/Day
Other Names:
|
Placebo Comparator: 3
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Reduction From Baseline in Menstrual Blood Loss (MBL)
Time Frame: Baseline MBL over 3 menstrual cycles
|
reduction of menstrual blood loss in mL
|
Baseline MBL over 3 menstrual cycles
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Reported Outcome Measure of Limitations in Social or Leisure Activities Associated With Heavy Menstrual Bleeding
Time Frame: Baseline scores over 3 menstrual cycles
|
A positive unit change of the mean relects an improvement from baseline.
Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited
|
Baseline scores over 3 menstrual cycles
|
Patient Reported Outome Measure of Limitations in Physical Activities Associated With Heavy Menstrual Bleeding
Time Frame: Baseline scores over 3 menstrual cycles
|
A positive unit change of the mean relects an improvement from baseline.
Patient reported outcome scores had the following response categories: 1=not limited at all; 2=slightly limited; 3=moderately limited; 4=quite a bit limited; and 5=extremely limited
|
Baseline scores over 3 menstrual cycles
|
Responder Analysis - Reduction in Large Stains
Time Frame: Baseline over 3 mentrual cycles
|
Percentage of subjects who experienced a reduction from baseline in the frequency of large stains
|
Baseline over 3 mentrual cycles
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Freeman EW, Lukes A, VanDrie D, Mabey RG, Gersten J, Adomako TL. A dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding. Am J Obstet Gynecol. 2011 Oct;205(4):319.e1-7. doi: 10.1016/j.ajog.2011.05.015. Epub 2011 May 14.
- Lukes AS, Muse K, Richter HE, Moore KA, Patrick DL. Estimating a meaningful reduction in menstrual blood loss for women with heavy menstrual bleeding. Curr Med Res Opin. 2010 Nov;26(11):2673-8. doi: 10.1185/03007995.2010.526098. Epub 2010 Oct 13.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2006
Primary Completion (Actual)
May 1, 2008
Study Completion (Actual)
May 1, 2008
Study Registration Dates
First Submitted
November 9, 2006
First Submitted That Met QC Criteria
November 17, 2006
First Posted (Estimate)
November 20, 2006
Study Record Updates
Last Update Posted (Estimate)
May 13, 2015
Last Update Submitted That Met QC Criteria
April 23, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- XP12B-MR-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menorrhagia
-
BayerCompletedIdiopathic MenorrhagiaCroatia, South Africa, Colombia, Czech Republic, Jordan, Lebanon, Macedonia, The Former Yugoslav Republic of, Moldova, Republic of, Romania, Ukraine, Venezuela, Bosnia and Herzegovina, Syrian Arab Republic, Albania
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesHungary
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesMexico
-
Minerva Surgical, Inc.CompletedMenorrhagia Due to Benign CausesCanada
-
BayerCompletedIdiopathic MenorrhagiaCroatia, Saudi Arabia, Bulgaria, Jordan, Romania, Russian Federation, Turkey, United Arab Emirates, Kuwait, India, Pakistan, Serbia, Sri Lanka
-
Legacy Health SystemUnknownMenopause | Climacteric; Menorrhagia, MenopausalUnited States
-
University of Sao PauloRecruitingCardiovascular Diseases | Arterial Hypertension | Postmenopausal; MenorrhagiaBrazil
-
BayerCompletedMenorrhagia, DysmenorrheaJapan
-
Faculty of Medicine, SousseCentre Hôpital Universitaire Farhat HachedCompletedMetrorrhagia | Hysterectomy | Heavy Menstrual Bleeding | Abnormal Uterine Bleeding | Menorrhagia; PostmenopausalTunisia
-
University of Sao PauloRecruitingMotor Activity | Physical Inactivity | Postmenopausal; MenorrhagiaBrazil
Clinical Trials on Tranexamic acid tablets
-
Ferring PharmaceuticalsCompletedMenorrhagia | Heavy Menstrual BleedingUnited States
-
Ferring PharmaceuticalsCompletedMenorrhagia | Heavy Menstrual BleedingUnited States
-
Lawrence Charles HookeyQueen's UniversityCompleted
-
Henry Ford Health SystemRecruitingLichen Planus Pigmentosus | Erythema Dyschromicum Perstans | Ashy Dermatosis of RamirezUnited States
-
University of Alabama at BirminghamTerminated
-
Carlos A Acosta-OlivoCompletedBlood Loss, SurgicalMexico
-
Ain Shams UniversityUnknown
-
Icahn School of Medicine at Mount SinaiRecruiting
-
University of LiegeCompletedArthroplasty Complications | Hemorrhage Postoperative | Total Blood LossBelgium
-
London School of Hygiene and Tropical MedicineCompleted